Delving into the Latest Updates on XZP-5955 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

NTRK x ROS1

Action

inhibitors

Mechanism

NTRK inhibitors(Neurotrophic tyrosine kinase receptor inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases

Active Indication

Locally Advanced Lung Non-Small Cell CarcinomaNTRK fusion-positive solid tumorsLiver Cancer+ [2]

Inactive Indication-

Originator Organization

Xuanzhu Biopharmaceutical Co., Ltd.Startup

Active Organization

Xuanzhu Biopharmaceutical Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

1、评价XZP-5955在局部晚期或转移性实体瘤（包括NTRK或ROS1基因融合）患者的安全性和耐受性； 2、评价XZP-5955在NTRK基因融合的局部晚期或转移性实体瘤患者和ROS1基因融合的局部晚期或转移性非小细胞肺癌患者中的有效性； 3、探索血液ctDNA NTRK或ROS1融合和/或突变与XZP-5955的疗效关系以及XZP-5955的耐药机制。

[Translation]

1. Evaluate the safety and tolerability of XZP-5955 in patients with locally advanced or metastatic solid tumors (including NTRK or ROS1 gene fusions); 2. Evaluate the efficacy of XZP-5955 in patients with locally advanced or metastatic solid tumors with NTRK gene fusions and patients with locally advanced or metastatic non-small cell lung cancer with ROS1 gene fusions; 3. Explore the relationship between blood ctDNA NTRK or ROS1 fusions and/or mutations and the efficacy of XZP-5955 and the resistance mechanism of XZP-5955.

Start Date18 Nov 2021

Sponsor / Collaborator

Xuanzhu Biopharmaceutical Co., Ltd.Startup

100 Clinical Results associated with XZP-5955

Login to view more data

100 Translational Medicine associated with XZP-5955

Login to view more data

100 Patents (Medical) associated with XZP-5955

Login to view more data

100 Deals associated with XZP-5955

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Lung Non-Small Cell Carcinoma	Phase 2	China	Xuanzhu Biopharmaceutical Co., Ltd.Startup	06 Dec 2021
NTRK fusion-positive solid tumors	Phase 2	China	Xuanzhu Biopharmaceutical Co., Ltd.Startup	06 Dec 2021
Liver Cancer	Phase 2	China	Xuanzhu Biopharmaceutical Co., Ltd.Startup	18 Nov 2021
ROS1 positive Mesothelioma	Phase 2	China	Xuanzhu Biopharmaceutical Co., Ltd.Startup	18 Nov 2021
Reactive oxygen species 1 positive non-small cell lung cancer	Phase 1	China	Xuanzhu Biopharmaceutical Co., Ltd.Startup	30 Jan 2022